Antialzheimer activity in Hartley guinea pig assessed as reduction in amyloid beta (1 to 40) level in CSF at 60 mg/kg, po formulated with 1% CMC/0.5% Tween 80 after 12 hrs relative to vehicle-treated control
Antialzheimer activity in Hartley guinea pig assessed as reduction in amyloid beta (1 to 40) level in CSF at 60 mg/kg, po formulated with 1% CMC/0.5% Tween 80 after 8 hrs relative to vehicle-treated control
Antialzheimer activity in Hartley guinea pig assessed as reduction in amyloid beta (1 to 40) level in CSF at 60 mg/kg, po formulated with 1% CMC/0.5% Tween 80 after 5 hrs relative to vehicle-treated control
Antialzheimer activity in Hartley guinea pig assessed as reduction in amyloid beta (1 to 40) level in CSF at 60 mg/kg, po formulated with 1% CMC/0.5% Tween 80 after 3 hrs relative to vehicle-treated control
Antialzheimer activity in Hartley guinea pig assessed as reduction in amyloid beta (1 to 40) level in CSF at 60 mg/kg, po formulated with 1% CMC/0.5% Tween 80 after 1 hr relative to vehicle-treated control
Antialzheimer activity in Hartley guinea pig assessed as reduction in amyloid beta (1 to 40) level in CSF at 100 mg/kg, po formulated with 1% CMC/0.5% Tween 80 after 3 hrs relative to vehicle-treated control
Antialzheimer activity in Hartley guinea pig assessed as reduction in amyloid beta (1 to 40) level in CSF at 30 mg/kg, po formulated with 1% CMC/0.5% Tween 80 after 3 hrs relative to vehicle-treated control
Antialzheimer activity in Hartley guinea pig assessed as reduction in amyloid beta (1 to 40) level in CSF at 10 mg/kg, po formulated with 1% CMC/0.5% Tween 80 after 3 hrs relative to vehicle-treated control